About Lipella
Lipella is a company based in Pittsburgh (United States) founded in 2005.. Lipella has raised $3.37 million across 16 funding rounds from investors including HHS. The company has 7 employees as of December 31, 2024. Lipella offers products and services including LP-10, LP-310, LP-410, and LP-50. Lipella operates in a competitive market with competitors including TheraVida, Esprit Pharma, Regenfro Co, Kissei Pharmaceutical and Acerus Pharma, among others.
- Headquarter Pittsburgh, United States
- Employees 7 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Lipella Pharmaceuticals Inc.
-
Annual Revenue
$536.36 K19.29as on Dec 31, 2024
-
Net Profit
$-5.02 M-8.6as on Dec 31, 2024
-
EBITDA
$-5.08 M-7.03as on Dec 31, 2024
-
Total Equity Funding
$3.37 M (USD)
in 16 rounds
-
Latest Funding Round
$3.79 M (USD), Post-IPO
Mar 04, 2025
- Investors
-
Employee Count
7
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Lipella
Lipella is a publicly listed company on the OTC with ticker symbol LIPO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Lipella
Lipella offers a comprehensive portfolio of products and services, including LP-10, LP-310, LP-410, and LP-50. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Drug targeting bladder inflammation after radiation, based on clinical trial results.
Therapy for chronic oral inflammation with positive Phase 2a trial outcomes.
Drug for managing oral complications in transplant patients.
Potential therapy for bladder cancer using liposomal delivery technology.
Unlock access to complete
Funding Insights of Lipella
Lipella has successfully raised a total of $3.37M across 16 strategic funding rounds. The most recent funding activity was a Post-IPO round of $3.79 million completed in March 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 16
- Last Round Post-IPO — $3.8M
-
First Round
First Round
(01 Dec 2005)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2025 | Amount | Post-IPO - Lipella | Valuation |
investors |
|
| Dec, 2024 | Amount | Post-IPO - Lipella | Valuation |
investors |
|
| Jul, 2024 | Amount | Post-IPO - Lipella | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Lipella
Lipella has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Lipella
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Lipella
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Lipella Comparisons
Competitors of Lipella
Lipella operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as TheraVida, Esprit Pharma, Regenfro Co, Kissei Pharmaceutical and Acerus Pharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Clinical stage biopharma company developing drugs for urology and central nervous system disorders
|
|
| domain | founded_year | HQ Location |
Develop drugs for genitourinary (GU) disorders
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics to treat renal diseases
|
|
| domain | founded_year | HQ Location |
Therapies for renal diseases and urology-related anemia are developed.
|
|
| domain | founded_year | HQ Location |
Develops pharmaceuticals for urology, hormone replacement therapy, and female sexual dysfunction treatments.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Lipella
Frequently Asked Questions about Lipella
When was Lipella founded?
Lipella was founded in 2005.
Where is Lipella located?
Lipella is headquartered in Pittsburgh, United States. It is registered at Pittsburgh, Pennsylvania, United States.
Is Lipella a funded company?
Lipella is a funded company, having raised a total of $3.37M across 16 funding rounds to date. The company's 1st funding round was a Post-IPO of $120.09K, raised on Dec 01, 2005.
How many employees does Lipella have?
As of Dec 31, 2024, the latest employee count at Lipella is 7.
What is the annual revenue of Lipella?
Annual revenue of Lipella is $536.36K as on Dec 31, 2024.
What does Lipella do?
Lipella was founded in 2005 in Pittsburgh, United States, within the biotechnology sector. Lipid-based therapies for bladder conditions are developed, focusing on intravesical delivery through urethral catheterization. Conditions addressed include interstitial cystitis, overactive bladder, and superficial bladder cancer. Formulations of multilamellar sphingomyelin liposomes are employed, binding to the bladder wall to establish a lipid barrier that supports tissue repair and shields against urinary irritants.
Who are the top competitors of Lipella?
Lipella's top competitors include Kissei Pharmaceutical, Regenfro Co and Esprit Pharma.
What products or services does Lipella offer?
Lipella offers LP-10, LP-310, LP-410, and LP-50.
Is Lipella publicly traded?
Yes, Lipella is publicly traded on OTC under the ticker symbol LIPO.
Who are Lipella's investors?
Lipella has 1 investor. Key investors include HHS.
What is Lipella's ticker symbol?
The ticker symbol of Lipella is LIPO on OTC.